New MenaQ7® Vitamin K2 Patents GrantedNew MenaQ7® Vitamin K2 Patents Granted
NattoPharma ASA has announced it has successfully secured patents in Israel, the United States, and Australia for its nature-identical synthesis creating MenaQ7® PharmaPure Vitamin K2 as MK-7, enriching the company’s already robust patent portfolio.
November 7, 2017
NattoPharma ASA has announced it has successfully secured patents in Israel, the United States and Australia for its nature-identical synthesis creating MenaQ7® PharmaPure Vitamin K2 as MK-7, enriching the company’s already robust patent portfolio.
• Israel: On July 31, 2017 patent #238199 “Process for preparation of MK-7 type of Vitamin K2” was granted.
• United States: On August 28, 2017 Notice of Allowance for patent #14/435,260 “Process for preparation of MK-7 type vitamin K2” was issued.
• Australia: On July 5, 2017 Notice of Acceptance (NoA) was issued for patent #2013330517 “process for preparation of MK-7 type of vitamin K2”. This NoA was published on July 20.
“This unique patented process results in the world’s only truly all-trans synthetic Vitamin K2 as MK-7,” says William Sommer, NattoPharma’s Vice President of Global Development & Regulatory. “Our material is of the highest quality and superior to anything else on the market, so much so that it currently be utilized in two studies sponsored by the traditional medical community.
“These studies are evidence that the medical community recognizes the difference a vitamin can make for human health, and in selecting MenaQ7 PharmaPure, they want to use the purest, all-trans material for future further confirmation and discovery of health benefits,” he continues. “This technology also ensures supplement providers deliver the MK-7 with the health benefits consumers desire.”
Sommer adds that NattoPharma has made significant intellectual and monetary investments in technologies, and that the company is committed to actively monitor market developments to protect the company’s intellectual property rights throughout their lifespan.
“The approval of these patents represents another milestone for NattoPharma and our partners,” concludes Sommer. “This further strengthens NattoPharma’s global IPRplatform and improve our competitive position in the within the food supplement market.”
About NattoPharma and MenaQ7®
NattoPharma ASA, based in Norway, is the world’s leader in vitamin K2 research and development. NattoPharma is the exclusive international supplier of MenaQ7® Vitamin K2 as MK-7, the best documented, vitamin K2 as menaquinone-7 (MK-7) with guaranteed actives and stability, clinical substantiation, and
international patents granted and pending, and now the new MenaQ7® Full Spectrum, which delivers menaquinones 6, 7, 8, and 9. The company has a multi-year research and development program to substantiate and discover the health benefits of vitamin K2 for applications in the marketplace for functional food and dietary supplements. With a global presence, the company established its North American subsidiary, NattoPharma USA, Inc., in Edison, NJ, and NattoPharma R&D Ltd. in Cyprus. For more information, visit www.nattopharma.com or www.menaq7.com.
You May Also Like
Advancing gender equity in the nutraceutical industrySep 25, 2023
CRN petition to FTC: RCTs aren’t required to substantiate ‘health-benefit’ claimsSep 22, 2023
Exercise recovery: Electrolytes, hydration and combating fatigue—SupplySide intensive webinarSep 22, 2023
Collagen peptide ingredient solutions for seniors’ changing needs – infographicSep 19, 2023